ATE540034T1 - Ä4-(6-halo-7-substituierte-2,4-dioxo-1,4-dihydr - 2h-chinazolin-3-yl)-phenylü-5-chloro-thiophen-2 yl-sulfonylharnstoffe und relevante formen und verfahren - Google Patents

Ä4-(6-halo-7-substituierte-2,4-dioxo-1,4-dihydr - 2h-chinazolin-3-yl)-phenylü-5-chloro-thiophen-2 yl-sulfonylharnstoffe und relevante formen und verfahren

Info

Publication number
ATE540034T1
ATE540034T1 AT06827506T AT06827506T ATE540034T1 AT E540034 T1 ATE540034 T1 AT E540034T1 AT 06827506 T AT06827506 T AT 06827506T AT 06827506 T AT06827506 T AT 06827506T AT E540034 T1 ATE540034 T1 AT E540034T1
Authority
AT
Austria
Prior art keywords
phenylu
dihydr
sulfonylureas
thiophen
quinazoline
Prior art date
Application number
AT06827506T
Other languages
English (en)
Inventor
Wolin Huang
Mukund Mehrotra
Xiaoming Zhang
Hilary Cannon
Craig M Grant
Robert M Scarborough
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Application granted granted Critical
Publication of ATE540034T1 publication Critical patent/ATE540034T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT06827506T 2005-11-03 2006-11-03 Ä4-(6-halo-7-substituierte-2,4-dioxo-1,4-dihydr - 2h-chinazolin-3-yl)-phenylü-5-chloro-thiophen-2 yl-sulfonylharnstoffe und relevante formen und verfahren ATE540034T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73365005P 2005-11-03 2005-11-03
PCT/US2006/043093 WO2007056219A2 (en) 2005-11-03 2006-11-03 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Publications (1)

Publication Number Publication Date
ATE540034T1 true ATE540034T1 (de) 2012-01-15

Family

ID=38023842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06827506T ATE540034T1 (de) 2005-11-03 2006-11-03 Ä4-(6-halo-7-substituierte-2,4-dioxo-1,4-dihydr - 2h-chinazolin-3-yl)-phenylü-5-chloro-thiophen-2 yl-sulfonylharnstoffe und relevante formen und verfahren

Country Status (21)

Country Link
US (3) US8058284B2 (de)
EP (2) EP1951254B1 (de)
JP (1) JP5509406B2 (de)
KR (1) KR101423483B1 (de)
CN (1) CN101300013B (de)
AR (1) AR056762A1 (de)
AT (1) ATE540034T1 (de)
AU (1) AU2006311795B2 (de)
BR (1) BRPI0618210A2 (de)
CA (1) CA2627719C (de)
CY (1) CY1112826T1 (de)
DK (1) DK1951254T3 (de)
EA (1) EA017402B1 (de)
ES (1) ES2380814T3 (de)
HK (1) HK1121051A1 (de)
IL (1) IL191193A (de)
NZ (2) NZ596025A (de)
PT (1) PT1951254E (de)
TW (2) TW200728260A (de)
WO (2) WO2007056219A2 (de)
ZA (1) ZA200804241B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1968922A (zh) 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
WO2007131179A1 (en) 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008133155A1 (ja) 2007-04-19 2008-11-06 Astellas Pharma Inc. 二環式ヘテロ環化合物
US20080279845A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
EP2076510A2 (de) * 2007-05-02 2009-07-08 Portola Pharmaceuticals, Inc. [4-(6-fluor-7-methylamino-2,4-dioxo-1,4-dihydro-2h-chinazolin-3-yl)phenyl]-chlorthiophen-2-yl-sulfonylharnstoffsalze in verschiedenen kristallinen formen, pharmazeutische zusammensetzungen davon und formulierungen davon zur behandlung von thrombose und thromboseähnlichen leiden
EP2079464A2 (de) 2007-05-02 2009-07-22 Portola Pharmaceuticals, Inc. Intravenöse und orale dosierung eines direkt wirkenden und reversiblen p2y12-hemmers
BRPI0812912A2 (pt) * 2007-06-18 2014-12-09 Sanofi Aventis Derivados de pirrol como antagonistas de p2y12
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
WO2010057036A2 (en) * 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
TW201109339A (en) 2009-08-28 2011-03-16 Daiichi Sankyo Co Ltd 3-(biaryloxy) propionic acid derivative
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
JP5796872B2 (ja) 2009-12-17 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の結晶性塩
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
US8987285B2 (en) * 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
RU2556198C1 (ru) * 2014-04-10 2015-07-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ профилактики развития постперикардиотомного синдрома у больных ишемической болезнью сердца, подвергшихся коронарному шунтированию
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE845042C (de) 1950-07-14 1952-07-28 Basf Ag Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6268380B1 (en) 1993-02-19 2001-07-31 G. D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
AU6395094A (en) 1993-03-15 1994-10-11 G.D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
TW448161B (en) 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
JPH0881442A (ja) 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd 環状アミド誘導体
US6413724B1 (en) 1996-10-28 2002-07-02 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
JPH10195323A (ja) 1997-01-09 1998-07-28 Nippon Paper Ind Co Ltd 新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
AU2219599A (en) 1998-01-15 1999-08-02 Millennium Pharmaceuticals, Inc. Platelet adp receptor inhibitors
JP2000204081A (ja) 1998-02-05 2000-07-25 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造法及び用途
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DK1257550T3 (da) 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
WO2003059288A2 (en) * 2002-01-09 2003-07-24 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
DE602004024093D1 (de) 2003-10-03 2009-12-24 Portola Pharm Inc 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
EP2076510A2 (de) * 2007-05-02 2009-07-08 Portola Pharmaceuticals, Inc. [4-(6-fluor-7-methylamino-2,4-dioxo-1,4-dihydro-2h-chinazolin-3-yl)phenyl]-chlorthiophen-2-yl-sulfonylharnstoffsalze in verschiedenen kristallinen formen, pharmazeutische zusammensetzungen davon und formulierungen davon zur behandlung von thrombose und thromboseähnlichen leiden
EP2079464A2 (de) * 2007-05-02 2009-07-22 Portola Pharmaceuticals, Inc. Intravenöse und orale dosierung eines direkt wirkenden und reversiblen p2y12-hemmers

Also Published As

Publication number Publication date
WO2007056167A3 (en) 2007-10-04
NZ596025A (en) 2013-08-30
IL191193A (en) 2014-04-30
EP1951254B1 (de) 2012-01-04
US20120088736A1 (en) 2012-04-12
EA017402B1 (ru) 2012-12-28
TW200728260A (en) 2007-08-01
US20070123547A1 (en) 2007-05-31
EP1951254A4 (de) 2009-05-27
WO2007056219A2 (en) 2007-05-18
EP1951254A2 (de) 2008-08-06
AU2006311795B2 (en) 2013-01-17
CN101300013A (zh) 2008-11-05
PT1951254E (pt) 2012-04-12
KR101423483B1 (ko) 2014-07-28
TW200804356A (en) 2008-01-16
WO2007056219A3 (en) 2007-12-27
WO2007056167A2 (en) 2007-05-18
AR056762A1 (es) 2007-10-24
HK1121051A1 (de) 2009-04-17
CA2627719C (en) 2016-07-12
CY1112826T1 (el) 2016-02-10
BRPI0618210A2 (pt) 2011-08-23
DK1951254T3 (da) 2012-05-07
NZ567747A (en) 2011-11-25
JP5509406B2 (ja) 2014-06-04
TWI397529B (zh) 2013-06-01
CA2627719A1 (en) 2007-05-18
ZA200804241B (en) 2009-09-30
US8058284B2 (en) 2011-11-15
KR20080071167A (ko) 2008-08-01
ES2380814T3 (es) 2012-05-18
EA200801245A1 (ru) 2008-10-30
EP2428514A1 (de) 2012-03-14
CN101300013B (zh) 2012-11-28
US20070208045A1 (en) 2007-09-06
JP2009515836A (ja) 2009-04-16
AU2006311795A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
ATE540034T1 (de) Ä4-(6-halo-7-substituierte-2,4-dioxo-1,4-dihydr - 2h-chinazolin-3-yl)-phenylü-5-chloro-thiophen-2 yl-sulfonylharnstoffe und relevante formen und verfahren
DE602006013492D1 (de) Verfahren und zwischenprodukte
DE602005009537D1 (de) Änger mit niedriger zf und assoziiertes verfahren
DE602006000297D1 (de) Verbinder , Verbinderprüfgerät und Verfahren
DE602006010154D1 (de) Biometrisches System und biometrisches Verfahren
DE602006009036D1 (de) Hängendes Bauelement und Herstellungsverfahren
DE602005017080D1 (de) Toner und tonerherstellungsprozess
DE602006005211D1 (de) HARQ-Verfahren und -System
DE602006009479D1 (de) Rohraufzug und entsprechendes Verfahren
DE602006016666D1 (de) Kommunikationsvorrichtung und Verfahren
DE602006009540D1 (de) L und herstellungsverfahren dafür
DE602006015873D1 (de) Verbinder und Montageverfahren
DE602006020117D1 (de) Nadellager und herstellungsverfahren dafür
DE602006000810D1 (de) Verbinder und Montageverfahren
BRPI0614961A2 (pt) aptâmero, método, e, composição
DE602006005208D1 (de) Tonerzusammensetzung und Verfahren
ATE401789T1 (de) Vorrichtung
DE502006009351D1 (de) Feinteiliges azopigment und verfahren zu seiner herstellung
ITMO20050167A1 (it) Apparati e metodi.
DE602006018129D1 (de) Codierer, decodierer und verfahren dafür
DE602006002891D1 (de) Flammendetektor und verfahren
DE602006014866D1 (de) Elastisches polyurethangarn und verfahren zu seiner herstellung
DE602006010414D1 (de) Haarknüpfwerkzeug und herstellungsverfahren dafür
DE602006012689D1 (de) Überprüfungsverfahren
FI20055682A0 (fi) Läpivientiosa sekä menetelmä